second-line options in cll: progressing on ibrutinib
Published 6 years ago • 135 plays • Length 5:09Download video MP4
Download video MP3
Similar videos
-
0:55
factors identified for risk of second cancer in cll following btk treatment
-
20:40
cll: treatment for btki progressors
-
2:56
second-line treatment in chronic lymphocytic leukemia
-
5:34
case 2: 17p-deleted cll progressing on ibrutinib therapy
-
3:22
treatment strategies with ibrutinib in cll
-
29:14
ibrutinib resistance-mechanisms and options in cll
-
1:07
ibrutinib plus venetoclax as a treatment option for cll
-
25:38
cll: chemotherapy and ibrutinib based regimens
-
6:32
ibrutinib therapy in chronic lymphocytic leukemia
-
5:00
upfront ibrutinib in cll
-
3:21
ibrutinib and other options for cll
-
1:02:27
personalized treatment with emerging btk inhibitor options in cll/sll and mcl
-
0:43
using acalabrutinib in cll patients with ibrutinib intolerance
-
5:19
additional insights: management of ibrutinib in cll
-
27:18
novel treatment options in cll
-
6:20
case 1: the use of ibrutinib in cll
-
3:28
case 4: resistance to ibrutinib in cll
-
59:40
challenges and changes with targeted options in cll
-
0:43
using acalabrutinib in the event of an intolerance to ibrutinib in cll